Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 8/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27254126 | 0.93 | LMNA (0.48) | LMNAMAOAPTGS1SCN4AKCNA3 | |
| SCHEMBL12978498 | 0.87 | LMNA (0.45) | LMNA | |
| SCHEMBL13085598 | 0.86 | LMNA (0.37) | LMNAMAOAPTGS1SCN4ALTA4H | |
| SCHEMBL27438647 | 0.83 | LMNA (0.36) | LMNAMAOAPTGS1SCN4ALTA4H | |
| SCHEMBL12098568 | 0.83 | ALDH1A1 (0.50) | LMNAMAOAPTGS1SCN4APLA2G2A | |
| SCHEMBL26802641 | 0.81 | ALDH1A1 (0.40) | LMNALTA4HPLA2G2APLA2G10PLA2G1B | |
| SCHEMBL6882239 | 0.81 | MTNR1A (0.48) | LMNA | |
| SCHEMBL10038814 | 0.81 | TSHR (0.44) | PLA2G2APLA2G10 | |
| SCHEMBL27250609 | 0.80 | MAPK1 (0.43) | LMNA | |
| SCHEMBL21398845 | 0.79 | TSHR (0.42) | PLA2G2APLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232169-A1 | HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES | BIOZONE PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232169-A1 | HIGHLY MONODISPERSE BRANCHED PEG-LIPID CONJUGATES | LIPA, CETP, DGAT2 | LMNA 3678/4885MAOA 4163/4885PTGS1 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.